Mitsubishi UFJ Kokusai Asset Management Co. Ltd. cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 12.3% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 119,700 shares of the company’s stock after selling 16,816 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries Limited were worth $3,976,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the stock. Greylin Investment Mangement Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 36.9% in the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock worth $9,783,000 after buying an additional 79,300 shares during the last quarter. PGGM Investments raised its position in shares of Teva Pharmaceutical Industries Limited by 12.0% in the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock worth $50,763,000 after buying an additional 163,292 shares during the last quarter. Schulhoff & Co. Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock worth $372,000 after buying an additional 1,004 shares during the last quarter. Heritage Investors Management Corp raised its position in shares of Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock worth $6,065,000 after buying an additional 28,135 shares during the last quarter. Finally, Bank Hapoalim BM raised its position in shares of Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after buying an additional 980 shares during the last quarter. 56.27% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited (TEVA) opened at 17.30 on Friday. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $55.39. The firm’s market capitalization is $17.58 billion. The stock’s 50 day moving average price is $29.64 and its 200-day moving average price is $31.56.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the business posted $1.25 EPS. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be paid a $0.085 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.97%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is currently -18.95%.

WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-shares-sold-by-mitsubishi-ufj-kokusai-asset-management-co-ltd/1477496.html.

A number of brokerages have weighed in on TEVA. Jefferies Group LLC restated a “hold” rating and issued a $26.00 price objective (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Deutsche Bank AG restated a “buy” rating and issued a $28.00 price objective (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Maxim Group restated a “hold” rating and issued a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Friday, August 4th. Sanford C. Bernstein lowered Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $42.00 to $28.00 in a report on Friday, August 4th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective (down previously from $31.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Three analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $37.69.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.